The pharmacological basis of anti-IgE therapy

@article{Chang2000ThePB,
  title={The pharmacological basis of anti-IgE therapy},
  author={Tse Wen Chang},
  journal={Nature Biotechnology},
  year={2000},
  volume={18},
  pages={157-162}
}
  • T. Chang
  • Published 1 February 2000
  • Biology, Medicine
  • Nature Biotechnology
The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II and III human clinical studies. The therapeutic efficacy of this approach is attributable to several pharmacological mechanisms. In addition to the expected effects of these monoclonal antibodies in neutralizing free IgE and inhibiting IgE production by B cells, several indirect biochemical and… 
Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases.
TLDR
The use of an anti-IgE antibody in the treatment of asthma was first suggested in preliminary studies in which omalizumab demonstrated efficacy in attenuating both the early- and late-phase bronchial responses to inhaled aeroallergens.
Will Anti-IgE Therapy Compromise Normal
TLDR
The IgE-mediated immune mechanism seems to have a modest role in the protection of human subjects against the infection of parasitic worms since the defense function is handled by several redundant immune mechanisms.
Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.
  • E. Schulman
  • Biology, Medicine
    American journal of respiratory and critical care medicine
  • 2001
TLDR
Preclinical and clinical studies have shown that specific inhibition of IgE may be an important new therapeutic option for the treatment of asthma and related disorders.
Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
TLDR
The paper emphasizes the central role IgE plays in allergic diseases and the biological rationale for its use, the evidence upon which the current recommendations for the use of anti-IgE in uncontrolled asthma are based and its possible future applications.
Anti-IgE as a mast cell-stabilizing therapeutic agent.
  • T. Chang, Y. Shiung
  • Biology, Medicine
    The Journal of allergy and clinical immunology
  • 2006
Experiences with monoclonal antibody therapy for allergic asthma.
  • H. Boushey
  • Medicine, Biology
    The Journal of allergy and clinical immunology
  • 2001
TLDR
Omalizumab reduced symptoms and exacerbations, improved lung function and quality of life, and reduced the need for rescue medications, when added to treatment with oral or inhaled corticosteroids, which persisted even in the "corticosteroid reduction" phase of these trials.
Anti-IgE therapy: clinical utility and mechanistic insights.
TLDR
Clinical observations and mechanistic studies with omalizumab have shed new light on the multifaceted roles of IgE in immune homeostasis and in allergic disease.
The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
TLDR
Anti-IgE therapy reduces leukotriene release of peripheral leukocytes stimulated with allergen in children with allergic rhinitis undergoing allergenic immunotherapy independent of the type of SIT allerGEN used.
...
...

References

SHOWING 1-10 OF 76 REFERENCES
Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation.
TLDR
Non-anaphylactogenic anti-IgE antibodies can markedly inhibit IgE levels and IgE-mediated allergic reactions, and since bronchoconstriction, BHR and lung eosinophilic inflammation can be suppressed, such antibodies may be attractive principles for the treatment of allergic asthma.
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.
TLDR
It is concluded that an anti-IgE monoclonal antibody, which inhibits binding of IgE to its receptor, suppresses the early- and late-phase responses to inhaled allergen in allergic asthmatic subjects.
Therapeutic potential of anti-IgE antibodies.
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
TLDR
A recombinant humanized monoclonal antibody directed against IgE has potential as a treatment for subjects with moderate or severe allergic asthma and was well tolerated.
Treatment of allergic asthma with monoclonal anti-IgE antibody.
TLDR
The efficacy of rhuMAb-E25 as a treatment for moderate-to-severe allergic asthma, a recombinant humanized monoclonal antibody that forms complexes with free IgE and blocks its interaction with mast cells and basophils is studied.
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.
TLDR
The use of anti-human IgE antibody is safe and effective in reducing serum IgE levels in atopic individuals and provides a potential therapeutic approach to the treatment of atopic diseases.
Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.
TLDR
Surprisingly, a few of the reshaped human C21 antibodies exhibited patterns of binding and affinities that were essentially identical to those of mouse C21 antibody.
Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.
TLDR
The solution characteristics of immune complexes formed by a humanized anti-IgE monoclonal antibody (rhuMAb E25) and IgE using sedimentation analysis and size exclusion chromatography are reported and it is shown that the largest complex may be represented by a cyclic structure.
Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response.
TLDR
The failure of anti-IgE to prevent the induction of IgE memory cells is discussed in terms of class switches that occur during the transition from IgM to IgE production.
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
TLDR
The inhibitory effects of rhuMAb-E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma.
...
...